bud flanagan leukaemia fund limitedEstimated Valuation
£23.5k
Pomanda estimates the enterprise value of BUD FLANAGAN LEUKAEMIA FUND LIMITED at £23.5k based on a Turnover of £24.7k and 0.95x industry multiple (adjusted for size and gross margin).
bud flanagan leukaemia fund limitedEstimated Valuation
£852.6k
Pomanda estimates the enterprise value of BUD FLANAGAN LEUKAEMIA FUND LIMITED at £852.6k based on an EBITDA of £133.6k and a 6.38x industry multiple (adjusted for size and gross margin).
bud flanagan leukaemia fund limitedEstimated Valuation
£1.8m
Pomanda estimates the enterprise value of BUD FLANAGAN LEUKAEMIA FUND LIMITED at £1.8m based on Net Assets of £754.1k and 2.45x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Bud Flanagan Leukaemia Fund LimitedOverview
Bud Flanagan Leukaemia Fund Limited is a live company located in east sussex, BN23 6EQ with a Companies House number of 04355397. It operates in the activities of other membership organizations n.e.c. sector, SIC Code 94990. Founded in January 2002, it's largest shareholder is
unknown.
Bud Flanagan Leukaemia Fund Limited is a mature,
micro sized company, Pomanda has estimated its turnover at
£24.7k with
rapid
growth in recent years.
Pomanda's financial health check has awarded Bud Flanagan Leukaemia Fund Limited a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 3 areas for improvement. Company Health Check FAQs
Health Rating4.5out of 5
4 Strong
2 Regular
3 Weak
Size
annual sales of £24.7k, make it smaller than the average company (£396.5k)
£24.7k - Bud Flanagan Leukaemia Fund Limited
£396.5k - Industry AVG
Growth
3 year (CAGR) sales growth of 39%, show it is growing at a faster rate (6.4%)
39% - Bud Flanagan Leukaemia Fund Limited
6.4% - Industry AVG
Production
with a gross margin of 96.2%, this company has a comparable cost of product (96.2%)
96.2% - Bud Flanagan Leukaemia Fund Limited
96.2% - Industry AVG
Profitability
an operating margin of 541.7% make it more profitable than the average company (2%)
541.7% - Bud Flanagan Leukaemia Fund Limited
2% - Industry AVG
Employees
with 1 employees, this is below the industry average (10)
1 - Bud Flanagan Leukaemia Fund Limited
10 - Industry AVG
Pay Structure
on an average salary of £28k, the company has an equivalent pay structure (£28k)
£28k - Bud Flanagan Leukaemia Fund Limited
£28k - Industry AVG
Efficiency
resulting in sales per employee of £24.7k, this is less efficient (£53.5k)
£24.7k - Bud Flanagan Leukaemia Fund Limited
£53.5k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Bud Flanagan Leukaemia Fund Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Bud Flanagan Leukaemia Fund Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Bud Flanagan Leukaemia Fund Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 2889 weeks, this is more cash available to meet short term requirements (142 weeks)
2889 weeks - Bud Flanagan Leukaemia Fund Limited
142 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 0.4%, this is a lower level of debt than the average (21.8%)
0.4% - Bud Flanagan Leukaemia Fund Limited
21.8% - Industry AVG
BUD FLANAGAN LEUKAEMIA FUND LIMITED financials
EXPORT
Bud Flanagan Leukaemia Fund Limited's latest turnover from December 2023 is £24.7 thousand and the company has net assets of £754.1 thousand. According to their latest financial statements, we estimate that Bud Flanagan Leukaemia Fund Limited has 1 employee and maintains cash reserves of £146.7 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Turnover
24,654
25,758
29,410
9,145
43,435
38,866
37,604
52,926
54,225
79,460
67,446
75,748
106,025
103,660
152,811
Other Income Or Grants
Cost Of Sales
948
411
5
8,370
23,266
35,273
33,798
38,480
52,937
53,194
Gross Profit
23,706
25,347
29,405
9,145
43,435
38,866
37,604
44,556
30,959
44,187
33,648
37,268
53,088
50,466
Admin Expenses
-109,854
19,262
24,217
8,970
51,834
41,486
35,807
48,469
24,899
47,085
869
7,944
114,208
49,863
36,298
Operating Profit
133,560
6,085
5,188
175
-8,399
-2,620
1,797
-3,913
6,060
-2,898
32,779
29,324
-61,120
603
-36,298
Interest Payable
Interest Receivable
Pre-Tax Profit
105,947
8,986
4,615
435
-4,249
1,752
4,026
-2,329
7,373
189
27,602
24,539
-58,049
2,755
-34,680
Tax
Profit After Tax
105,947
8,986
4,615
435
-4,249
1,752
4,026
-2,329
7,373
189
27,602
24,539
-58,049
2,755
-34,680
Dividends Paid
Retained Profit
105,947
8,986
4,615
435
-4,249
1,752
4,026
-2,329
7,373
189
27,602
24,539
-58,049
2,755
-34,680
Employee Costs
28,002
26,346
25,586
25,246
24,908
23,577
47,036
24,656
50,417
51,459
51,372
50,461
50,511
Number Of Employees
1
1
1
1
1
1
1
2
1
2
2
2
2
2
EBITDA*
133,560
6,085
5,188
175
-8,399
-2,620
1,797
-3,913
6,060
-2,898
32,779
29,324
-61,120
603
-36,298
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Tangible Assets
Intangible Assets
Investments & Other
610,000
500,294
500,294
358,158
166,257
Debtors (Due After 1 year)
Total Fixed Assets
610,000
500,294
500,294
358,158
166,257
Stock & work in progress
Trade Debtors
Group Debtors
Misc Debtors
1,730
3,740
640
Cash
146,700
146,732
139,484
276,683
467,820
638,851
636,627
632,548
634,877
627,504
627,315
599,713
586,094
642,186
647,086
misc current assets
total current assets
146,700
148,462
139,484
276,683
467,820
638,851
636,627
632,548
634,877
627,504
627,315
599,713
589,834
642,826
647,086
total assets
756,700
648,756
639,778
634,841
634,077
638,851
636,627
632,548
634,877
627,504
627,315
599,713
589,834
642,826
647,086
Bank overdraft
329
Bank loan
Trade Creditors
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities
2,640
643
651
525
53
14,660
9,603
16,618
total current liabilities
2,640
643
651
329
525
53
14,660
9,603
16,618
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
total long term liabilities
total liabilities
2,640
643
651
329
525
53
14,660
9,603
16,618
net assets
754,060
648,113
639,127
634,512
634,077
638,326
636,574
632,548
634,877
627,504
627,315
599,713
575,174
633,223
630,468
total shareholders funds
754,060
648,113
639,127
634,512
634,077
638,326
636,574
632,548
634,877
627,504
627,315
599,713
575,174
633,223
630,468
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Operating Activities
Operating Profit
133,560
6,085
5,188
175
-8,399
-2,620
1,797
-3,913
6,060
-2,898
32,779
29,324
-61,120
603
-36,298
Depreciation
Amortisation
Tax
Stock
Debtors
-1,730
1,730
-3,740
3,100
640
Creditors
Accruals and Deferred Income
1,997
-8
651
-525
472
53
-14,660
5,057
-7,015
16,618
Deferred Taxes & Provisions
Cash flow from operations
137,287
4,347
5,839
175
-8,924
-2,148
1,850
-3,913
6,060
-2,898
32,779
18,404
-59,163
-7,052
-19,680
Investing Activities
capital expenditure
Change in Investments
109,706
142,136
191,901
166,257
cash flow from investments
-109,706
-142,136
-191,901
-166,257
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue
665,148
interest
cash flow from financing
665,148
cash and cash equivalents
cash
-32
7,248
-137,199
-191,137
-171,031
2,224
4,079
-2,329
7,373
189
27,602
13,619
-56,092
-4,900
647,086
overdraft
-329
329
change in cash
-32
7,248
-136,870
-191,466
-171,031
2,224
4,079
-2,329
7,373
189
27,602
13,619
-56,092
-4,900
647,086
bud flanagan leukaemia fund limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for bud flanagan leukaemia fund limited. Get real-time insights into bud flanagan leukaemia fund limited's credit score, group structure and payment trends.
Bud Flanagan Leukaemia Fund Limited Competitor Analysis
Perform a competitor analysis for bud flanagan leukaemia fund limited by selecting its closest rivals, whether from the OTHER SERVICE ACTIVITIES sector, other micro companies, companies in BN23 area or any other competitors across 12 key performance metrics.
bud flanagan leukaemia fund limited Ownership
BUD FLANAGAN LEUKAEMIA FUND LIMITED group structure
Bud Flanagan Leukaemia Fund Limited has no subsidiary companies.
Ultimate parent company
BUD FLANAGAN LEUKAEMIA FUND LIMITED
04355397
BUD FLANAGAN LEUKAEMIA FUND LIMITED Shareholders
The sole shareholder of Bud Flanagan Leukaemia Fund Limited is -.
-
-
bud flanagan leukaemia fund limited directors
Bud Flanagan Leukaemia Fund Limited currently has 4 directors.
The longest serving directors include
Mr Martin King (May 2009) and
Ms Geraldine Smith (Feb 2019).
bud flanagan leukaemia fund limited company details
company number
04355397
Type
Private Ltd By Guarantee w/o Share Cap
industry
94990 - Activities of other membership organisations n.e.c.
incorporation date
January 2002
age
23
incorporated
UK
ultimate parent company
None
accounts
Total Exemption Full
last accounts submitted
December 2023
previous names
N/A
accountant
OLIVER READ
auditor
-
address
16 royal sovereign view, eastbourne, east sussex, BN23 6EQ
Bank
ALLIED IRISH BANK
Legal Advisor
-
bud flanagan leukaemia fund limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to bud flanagan leukaemia fund limited.
bud flanagan leukaemia fund limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for BUD FLANAGAN LEUKAEMIA FUND LIMITED. This can take several minutes, an email will notify you when this has completed.
bud flanagan leukaemia fund limitedCompanies House Filings - See Documents
